Lupin gets USFDA nod for oral suspension drug to treat seizures

PTI New Delhi | Updated on December 31, 2018 Published on December 31, 2018

Drug maker Lupin Monday said it has received approval from the US health regulator for Clobazam Oral Suspension, used to treat seizures associated with Lennox-Gastaut Syndrome.

The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Lundbeck Pharmaceuticals LLC’s Onfi Oral Suspension, Lupin said in a regulatory filing.

The drug is indicated for treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients of two years of age or older.

Clobazam Oral Suspension (2.5 mg/ml) had annual sales of around $260.2 million in the US.

Lupin shares Monday ended 0.78 per cent up at ₹ 845.60 on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on December 31, 2018
This article is closed for comments.
Please Email the Editor